FOLD Amicus Therapeutics Inc.

9.79
-0.62  -6%
Previous Close 10.41
Open 10.33
Price To Book 4.55
Market Cap 2,493,315,566
Shares 254,809,971
Volume 2,826,603
Short Ratio
Av. Daily Volume 3,383,826
Stock charts supplied by TradingView

NewsSee all news

  1. Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance

    2020 Galafold Revenue Guidance of $250M-$260M  Focused on Pompe Phase 3 PROPEL study and manufacturing to support 2021 BLA and MAA Continued Progress Across Industry Leading Rare Disease Gene Therapy Portfolio Strong

  2. Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance

    Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations Recently Received in

  3. Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease

    123 Patients Enrolled in Phase 3 PROPEL Study – Enrollment Completed in 4Q2019 Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition of Full Clinical

  4. Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates

               3Q19 Galafold® (migalastat) Revenue of $48.8M  and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M Complete Enrollment of

  5. Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019

    CRANBURY, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced August 10, 2018.
Migalastat
Fabry Disease
Phase 3 top-line data released September 13, 2017 - endpoints not met.
SD-101
Epidermolysis Bullosa (EB)
Phase 1/2 trial ongoing.
CLN6 Gene Therapy
Batten disease
Phase 3 propel enrolment completed 4Q 2020. Rolling BLA filing to be submitted 2020. To be completed with full data 1H 2021.
AT-GAA - Propel
Pompe Disease
Phase 1/2 initial data due 2020.
AAV9-CLN3
Batten disease

Latest News

  1. Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance

    2020 Galafold Revenue Guidance of $250M-$260M  Focused on Pompe Phase 3 PROPEL study and manufacturing to support 2021 BLA and MAA Continued Progress Across Industry Leading Rare Disease Gene Therapy Portfolio Strong

  2. Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance

    Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations Recently Received in

  3. Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease

    123 Patients Enrolled in Phase 3 PROPEL Study – Enrollment Completed in 4Q2019 Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition of Full Clinical

  4. Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates

               3Q19 Galafold® (migalastat) Revenue of $48.8M  and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M Complete Enrollment of

  5. Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019

    CRANBURY, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to

  6. Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day

    Analyst Day 2019 to Highlight Financial Outlook andRobust Portfolio of Novel Therapies for Rare Metabolic Diseases 3Q19 Galafold® (migalastat) Preliminary Unaudited Revenue of ~$48M+  and 1,000+ Patients on Therapy

  7. Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society

    Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24 Data in Additional Switch Patients (Cohort 4) Consistent

  8. Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019

    CRANBURY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming Medical Conferences:

  9. Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019

    CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell, President and Chief